Genzyme

ILEX is a drug development company focused exclusively on oncology. The company uses its expertise in the identification, development, manufacturing and regulatory approval process of oncology drugs to: (i) develop cancer treatment products, (ii) develop products for the prevention of cancer and (iii) provide contract research services to pharmaceutical and biotechnology companies. ILEX's objective is to be a leading worldwide oncology drug development company. The company has nine cancer treatment compounds under development, including five in Phase II or Phase III clinical trials. In October 1996, ILEX submitted a NDA to the FDA seeking accelerated marketing approval for MGBG as a second-line treatment for patients with AIDS-related non-Hodgkin's lymphoma. Additionally, ILEX has two chemoprevention compounds under development. Consistent with its strategy, the Company has established worldwide development and marketing collaborations with Sanofi, Janssen and MGI Pharma for certain of its compounds. In addition to its proprietary product development programs, the company offers CRO services to both the pharmaceutical and biotechnology industries. ILEX believes it is currently the only full-service provider of contract research services focused exclusively on oncology. ILEX was formed by CTRC in December 1993 for the purpose of conducting certain advanced drug development programs and pursuing commercial opportunities which were not within the scope of CTRC's tax-exempt purpose.

SangStat Medical Corporation, a global biopharmaceutical company, engages in the discovery, development, and marketing of therapeutic products for immunology, transplantation medicine, hematology/oncology, and autoimmune disorders.

Alnylam (Nasdaq: ALNY) is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

PharmaGenics develops therapeutic products for cancer through the use of genomics technology.

Bioenvision a biopharmaceutical company, engages in the acquisition, development, and marketing of compounds and technologies primarily for the treatment of cancer. Its lead products include Evoltra (clofarabine) which has marketing approval in both the European Union and United States for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia and Modrenal (trilostane), which has marketing approval in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy.

Peptimmune is a privately held clinical stage biotechnology company focused on utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders. The company is developing second generation therapeutics that are expected to result in safer and more effective products for obesity, multiple sclerosis, rheumatoid arthritis and pemphigus vulgaris.

Bone Care International, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat the medical needs of patients with debilitating conditions and life-threatening diseases.

AnorMED, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic drugs for the treatment of hematology, human immunodeficiency virus (HIV), and oncology. Its lead drug product candidate include MOZOBIL, which is under phase III clinical trial is used for cancer patients undergoing stem cell transplantation; and AMD070, which is under phase Ib/IIa trial is used as a HIV entry inhibitor.

Genzyme Biosurgery Corporation was engaged in the development, manufacture, marketing, and sale of a series of proprietary viscoelastic products, called hylans that are used in therapeutic medical applications and skin care.

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass.

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Verigen AG, a biotherapy company, provides cell therapy products for cartilage repair. It has operations in Germany, Australia, Denmark, Italy, England, Europe, and the United States.